Clinical Trial Update: A Randomized, Double-blind,Phase Ⅲ Study of Liposome Doxorubicin in Desmoid Tumor [Phase 3]

View source ↗

Summary

A Phase 3 randomized, double-blind trial evaluating liposome doxorubicin in desmoid tumor is ongoing; no results reported yet.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Desmoid Tumor

Drugs mentioned

• liposome doxorubicin (liposome doxorubicin)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Desmoid Tumor | Phase 3 | Status: UNKNOWN